epithalamin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
| Property | Value | Notes |
|---|---|---|
| Analytical method | Reversed-phase HPLC | Purity determination, typically 214 nm |
| Mass confirmation | ESI or MALDI mass spectrometry | Compared with mass near 390 Da |
| Common synonyms | Epitalon, epithalon, AEDG | Naming differs between suppliers |
| Storage temperature | −20 °C or lower | Lyophilised powder, kept desiccated |
| Solution stability | Limited in neutral aqueous buffer | Aspartimide and hydrolysis pathways |
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
The college's prospectus, published in 1884, offered three diplomas: Christian Scientist (C.S.) for Christian Scientists' Association members; Christian Metaphysician (C.M.) for Eddy's 12-lesson course and three years' practice; and Doctor of Christian Science (D.C.S.) for C.M.s whose "life and character conform to Divine science." In 1886, the Bachelor of Christian Science (C.S.B.) diploma was offered. Students could study metaphysics, science of the scriptures, mental healing and obstetrics, using two textbooks, Science and Health and the Bible. Between 1881 and October 1889, when Eddy closed the college, 4,000 students took the course at $300 per person or married couple, making her a rich woman. Mark Twain wrote sarcastically that she had turned a sawdust mine (possibly Quimby's) into a Klondike.
On 7 October 2023, a geopolitical conflict began between the State of Israel and Hamas in the Gaza Strip region, which significantly shook the international community. Brazil, at first, did not classify Hamas as a terrorist organization, since the country's policy on this issue directly agrees with the UN classification, which also did not classify it as a terrorist. On the same day, the Ministry of Foreign Affairs and the federal government organized a rescue operation for Brazilians who were in Israel, being the first country to do so. Days later, several planes belonging to the Brazilian Air Force were sent to the region of Israel in order to rescue Brazilians who wanted to go back to Brazil. On his social networks, President Lula made a post in which he condemned the Hamas attacks and described Brazil as capable of "finding a path to peace". Lula also published that he spoke to Israeli president Isaac Herzog and ratified his repudiation of the events, while also calling for Israel to take all measures to prevent a humanitarian crisis. He also later spoke with the Mahmoud Abbas, president of the Palestinian Authority, and Abdul Fatah Khalil Al-Sisi, president of Egypt. On 20 October, Lula spoke out again on social media, classifying the Hamas attack as an "act of madness" and "terrorism against Israel", and Israel's response as "insane", citing the high mortality rate (especially of children and infants) in Gaza during the bombings and invasion.
=== Preclinical === AM-510 – undefined mechanism of action – opioid-related disorders ATI-1013 – monoclonal antibody against nicotine – smoking withdrawal CTRX-1001 – immunostimulant – opioid-related disorders CTRX-2001 – immunostimulant – opioid-related disorders Cyclobenzaprine (KRL-102; TNX-102; Tonmya; VLD-cyclobenzaprine) – tricyclic antidepressant (various actions) – alcoholism Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – cocaine-related disorders Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders Flumazenil/naloxone transdermal patch (MX-1607; RescuePatch) – combination of flumazenil (GABAA receptor negative allosteric modulator/benzodiazepine antagonist) and naloxone (opioid receptor antagonist) – substance-related disorders GM-3009 – κ-opioid receptor agonist (noribogaine analogue) – opioid-related disorders INDV-1000 (GABAB PAM) – GABAB receptor positive allosteric modulator – substance-related disorders KB-128 – serotonin 5-HT2C receptor G protein-biased agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist – alcoholism LPH-48 – undefined mechanism of action and serotonergic psychedelic ((shorter-acting LPH-5 analogue) – alcoholism M-101 – GABA receptor antagonist – substance-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – cocaine-related disorders Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – substance-related disorders Midomafetamine microneedle transdermal patch (MDMA; ecstasy) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, entactogen – substance-related disorders Naltrexone controlled-release (BICX101, BICX-101) – opioid receptor antagonist – alcoholism, opioid-related disorders Nicotine degrading enzyme (ATI-3009; NicA2; NicA2-J1) – enzyme – smoking withdrawal PPL-138 (BU10038, BU-10038) – nociceptin receptor agonist, μ-opioid receptor agonist, opioid peptide agonist – alcoholism, cocaine-related disorders PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders Psilacetin (O-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – substance-related disorders Pudafensine (IP-2015; IP-2017; IPNP-2015; IPTN-2021) – serotonin–norepinephrine–dopamine reuptake inhibitor – substance-related disorders Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism of action and serotonergic psychedelics – alcoholism Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders SVN-015 – serotonin–dopamine reuptake inhibitor – substance-related disorders SXC-2023 – cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator – cocaine-related disorders, smoking withdrawal [15] [16] TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism TACT523 – undefined mechanism of action – alcoholism TACT833 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism VS-01 (VS-01-HAC) – ammonia scavenger – substance-related disorders
In 1874 Jacobus Henricus van 't Hoff and Joseph Le Bel independently proposed the tetrahedral arrangement of the atoms bound to carbon in organic molecules. Van't Hoff's theory validated and explained Pasteur's results with tartrate crystals, and Johannes Wislicenus' work with isomeric lactic acids, and was fundamental to the further development of stereochemistry. Until the use of X-rays there was no way to determine the actual crystal structure of even the simplest substances such as salt (NaCl). For example in the 1880s, William Barlow proposed several crystal structures based on close-packing of spheres some of which were validated later by X-ray crystallography; however, the available data were too scarce in the 1880s to accept his models as conclusive. In the period between the discovery of X-rays (1895) and X-ray diffraction (1912) Barlow and William Jackson Pope developed the principles of packing, and showed how to deduce the structures of some simple compounds. In the 1930s Linus Pauling was impressed that Barlow had assigned many crystal structures of metals (copper, silver, and gold to cubic close packing, and magnesium, zinc, and cadmium to hexagonal close packing) and salts (sodium, potassium and caesium chlorides) which were subsequently proved to be correct by X-ray crystallography. William Johnson Sollas emphasised the importance of different atomic sizes in constructing simple crystals, and correctly concluded that the sodium and chlorine atoms in salt would be of different sizes.
Cell division is essential for an organism to grow, but, when a cell divides, it must replicate the DNA in its genome so that the two daughter cells have the same genetic information as their parent. The double-stranded structure of DNA provides a simple mechanism for DNA replication. Here, the two strands are separated and then each strand's complementary DNA sequence is recreated by an enzyme called DNA polymerase. This enzyme makes the complementary strand by finding the correct base through complementary base pairing and bonding it onto the original strand. As DNA polymerases can only extend a DNA strand in a 5′ to 3′ direction, different mechanisms are used to copy the antiparallel strands of the double helix. In this way, the base on the old strand dictates which base appears on the new strand, and the cell ends up with a perfect copy of its DNA.
Sources: en.wikipedia.org
Monoclonal antibodies for research applications can be found directly from antibody suppliers, or through use of a specialist search engine like CiteAb. Below are examples of clinically important monoclonal antibodies.
=== Red blood cell rejuvenation === Red blood cell rejuvenation is a method which aims to increase the levels of 2,3-diphosphoglycerate (2,3-DPG) and ATP in stored red blood cell concentrates, as the levels of both 2,3-DPG and ATP decrease over time. The rejuvenation process includes incubation of the red blood cells with a rejuvenation solution and subsequent washing. ATP is an important driver of a number of metabolic functions of the red blood cell, and declined ATP levels have been linked to reduced post-transfusion in vivo survival of the red blood cells. High levels of 2,3-DPG facilitates oxygen unloading from the red blood cells in the capillaries.
== Pharmacology == Not much is understood about how benzoctamine produces its anti-anxiety effects, but rat studies have shown that the possible mechanism of action is by way of increased turnover of catecholamines. In addition to serotonin it has also been shown to decrease epinephrine, dopamine, and norepinephrine turnover by antagonizing their receptors. When given intravenously in doses of 20–40 mg there are no significant differences in efficacy. Oral doses exceeding 10 mg three times daily do not increase the effects of the drug. Assuming serotonin postsynaptic antagonism is the main mechanism by which benzoctamine carries out its effects, studies have shown it to have an IC50 value of 115 mM at the serotonin receptor.
==== Seed oil ==== Mature seeds yield 38–40% edible oil called ben oil from its high concentration of behenic acid. The refined oil is clear and odorless, and resists rancidity. The young fruits can be boiled and the oil skimmed off the water surface. The seed cake remaining after oil extraction may be used as a fertilizer or as a flocculent to purify water. Moringa seed oil also has potential for use as a biofuel.
absorption 1. The physical or chemical process by which a substance in one state becomes incorporated into and retained by another substance of a different state. Absorption differs from adsorption in that the first substance permeates the entire bulk of the second substance, rather than just adhering to the surface. 2. The process by which matter (typically electrons bound in atoms) takes up the energy of electromagnetic radiation and transforms it into any of various types of internal energy, such as thermal energy. This type of absorption is the principle on which spectrophotometry is based.
Sources: en.wikipedia.org
=== Early study === The history of oligopeptidases originates in the late 1960s, when the rabbit brain was searched for enzymes that cause inactivation of the nonapeptide bradykinin. In the early and mid 1970s two thiol-activated endopeptidases, responsible for more than 90% of bradykinin inactivation, were isolated from cytosol of rabbit brain, and characterized. They correspond to EOPA (endooligopeptidase A, EC 3.4.22.19), and Prolyl endopeptidase or Prolyl oligopeptidase (POP) (EC 3.4.21.26). Since their activities are restricted to oligopeptides (usually from 8-13 amino acid residues), and do not hydrolyze proteins or large peptides (>30 amino acid residues), they were designated oligopeptidases. In the early and mid 1980s other oligopeptidases, mostly metallopeptidases, were described in the cytosol of mammalian tissues, such as the TOP (thimet oligopeptidase, EC 3.4.24.15), and the neurolysin (EC 3.4.24.16). Earlier on, the ACE (angiotensin-converting enzyme, EC 3.4.15.1), and the NEP (neprilysin, EC 3.4.24.11), had been described, at the end of the 1960s, and in 1973, respectively.
=== Indiana === Indiana passed the first sterilization law in the United States, the 1907 Indiana Eugenics Law. It was proposed as a part of the Progressive-era wave in which public health advocacy began coming to light.
== Pharmacokinetics == Prucalopride is rapidly absorbed (Cmax attained 2–3 hours after single 2 mg oral dose) and is extensively distributed. Metabolism is not the major route of elimination. In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found. A large fraction of the active substance is excreted unchanged (about 60% of the administered dose in urine and at least 6% in feces). Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. Plasma clearance averages 317 ml/min, terminal half-life is 24–30 hours, and steady-state is reached within 3–4 days. On once daily treatment with 2 mg prucalopride, steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively. In vitro data indicate that prucalopride has a low interaction potential, and therapeutic concentrations of prucalopride are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products.
==== Supplementation ==== Supplementation is defined as the use of additional milk or fluid products to feed an infant, in addition to breastmilk, during the first 6 months of life. The Academy of Breastfeeding Medicine recommends only supplementing when medically indicated, as opposed to mixing use of formula and breastmilk for reasons that are not necessarily medical indications. Some medical indications for supplementation include low blood sugar, dehydration, excessive weight loss or poor gain, and jaundice in the infant; true low milk supply; severe nipple pain unrelieved by interventions; and medical contraindications to breastfeeding, as described below. Supplements can be delivered at the breast through a supplemental nursing system to stimulate the production of the mother's own milk and to preserve the breastfeeding relationship. Some parents may desire to supplement proactively if early signs of insufficient intake, such as decreased urination, dry mucous membranes, or persistent signs of hunger, are noticed. If these signs are noticed, it is important to have the mother-infant dyad evaluated by a breastfeeding specialist or pediatrician to determine the true cause of the symptoms and determine the need for supplementation. Often, these symptoms are caused by poor milk transfer at the breast and can be solved with adjustments to the latch. Occasionally, they may be caused by other processes, unrelated to breastfeeding, so evaluation is necessary.
The lucky survivor model (cluster ionization mechanism) postulates that analyte molecules are incorporated in the matrix maintaining the charge state from solution. Ion formation occurs through charge separation upon fragmentation of laser ablated clusters. Ions that are not neutralized by recombination with photoelectrons or counter ions are the so-called lucky survivors. The thermal model postulates that the high temperature facilitates the proton transfer between matrix and analyte in melted matrix liquid. Ion-to-neutral ratio is an important parameter to justify the theoretical model, and the mistaken citation of ion-to-neutral ratio could result in an erroneous determination of the ionization mechanism. The model quantitatively predicts the increase in total ion intensity as a function of the concentration and proton affinity of the analytes, and the ion-to-neutral ratio as a function of the laser fluences. This model also suggests that metal ion adducts (e.g., [M+Na]+ or [M+K]+) are mainly generated from the thermally induced dissolution of salt. The matrix-assisted ionization (MAI) method uses matrix preparation similar to MALDI but does not require laser ablation to produce analyte ions of volatile or nonvolatile compounds. Simply exposing the matrix with analyte to the vacuum of the mass spectrometer creates ions with nearly identical charge states to electrospray ionization. It is suggested that there are likely mechanistic commonality between this process and MALDI.
Sources: en.wikipedia.org
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.
Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.
No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.